10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
| Life Sciences Tools & Services Industry | Healthcare Sector | Serge Saxonov CEO | XMEX Exchange | US88025U1097 ISIN |
| US Country | 1,306 Employees | - Last Dividend | 17 Jul 2006 Last Split | 12 Sep 2019 IPO Date |
10x Genomics, Inc. is a prominent life science technology company known for its innovative development and commercialization of instruments, consumables, and software aimed at analyzing biological systems. The company's footprint extends across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific regions, catering to a diverse clientele that includes academic, government, biopharmaceutical, biotechnology, and other institutions. Originally named 10X Technologies, Inc., it underwent a rebranding to 10x Genomics, Inc. in November 2014. Since its inception in 2012, 10x Genomics has established its headquarters in Pleasanton, California, positioning itself as a leader in the field of genomics and cellular analysis.